1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Terminated 1 |
Follow E10030 sham injection: new trials by email Literature Review of E10030 sham injection trials Research Report on E10030 sham injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy E10030, bevacizumab or aflibercept, E10030 sham injection - Age-Related Macular Degeneration | Phase 3 | Terminated | Ophthotech Corporation | 645 | 2014-05-01 | 2024-10-31 |
Choroidal Neovascularization (1) · Macular Degeneration (1)
Argentina (1) · Australia (1) · Austria (1) · Brazil (1) · Canada (1) · Colombia (1) · Croatia (1) · Czechia (1) · Estonia (1) · Finland (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1)